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Summary: We have developed a non-competitive sandwich enzyme-linked immunosorbent assay for the
quantitation of apolipoprotein B, which utilizes the biotin-avidin amplification system. All components were
optimized with respect to either concentration or incubation time. The assay uses microtitre wells as a solid
phase and polyclonal, affinity-purified capture antibody. The amplification system was composed of hydroxy-
succinimide biotin conjugated to an affinity-purified anti-apolipoprotein B IgG and either ExtrAvidin-alkaline
phosphatase or streptavidin-alkaline phosphatase. The within-run precision (n = 10) of the apolipoprotein B
control (1.39 g/1) was 3%, while the between-run precision of the assay (n = 6) for 9 consecutive assays was
determined to be 8%. A sensitivity of 3 ng was attained, with a mean analytical recovery of 110%. Comparison
of the assay with an established immunoturbidometric method resulted in a correlation of 0.92 using patient
plasma samples (n = 19). The use of the biotin-avidin amplification system provides the sensitivity required
for measuring apolipoprotein B in tissue culture media samples and circumvents the many problems associated
with the direct conjugation of enzymes to antibodies. Minimal amounts of reagents are required and the
assay can be performed in 5 h, making it both economical and practical for clinical laboratories.
A considerable number of methods have been utilized
Apolipoprotein B is the major protein component of to quantitate plasma apolipoprotein B concentra-
very low density lipoprotein (VLDL) and low density tions. The majority of these assays are immunological
lipoprotein (LDL) in humans. It is a structural protein techniques such as immunonephelometry (4, 5), ra-
that allows lipids to be transported in the aqueous dioimmunoassay (RIA) (6, 7) and enzyme immuno-
plasma environment. In addition, apolipoprotein B assay (EIA) (8, 9). While immunonephelometric as-
binds to cell surface receptors and facilitates incor- says are fast and accurate, their sensitivity to the
poration of lipoproteins into peripheral tissues and turbidity of the sample and the requirement of the
organs. Increasing attention is being paid to deter- use of enzymes or detergents with hypertriglyceri-
minating apolipoprotein B concentrations in plasma, daemic samples are definite drawbacks (10). RIAs
due to evidence suggesting its usefulness in diagnosing developed for the determination of apolipoprotein B
and characterizing various types of dyslipidaemias(l). concentrations show good accuracy and sensitivity,
Measuring apolipoprotein B concentration may also but have several disadvantages, such as expensive
be useful in determining the severity of coronary heart reagents and the use of radioisotopes (10, 11). Quan-
disease (2) and in predicting the risk of its develop- titation of apolipoprotein B by El As such as enzyme-
ment (3). linked immunosorbent assay (ELISA) gives results
that are reproducible, accurate, and with a sensitivity
') This work was supported by a research grant from the Heart comparable to that of RIAs (10). This is accomplished
and Stroke Foundation of Ontario (AN 1901). without the use of radioisotopes as in RIAs, and
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without interference from sample turbidity as in im-
munoturbidometric methods. A few direct ELISA
assays have been developed for plasma apolipoprotein
B determinations (12-16). The major drawback with
these assays is the direct conjugation of apolipopro-
tein B antibody to an enzyme using harsh crosslinkers
such as glutaraldehyde or periodate which have a
potential for causing changes in antibody-antigen
binding, resulting in lower enzyme activity (17).
We have developed a non-competitive sandwich
ELISA for the measurement of apolipoprotein B con-
centrations utilizing the biotin-avidin amplification
system. The use of the biotin-avidin system circum-
vents the above problem with enzyme-antibody con-
jugation by using a biotinylated antibody that can be
prepared under mild and non-denaturing conditions.
In addition, the assay uses minimal amounts of rea-
gents and can be performed in a normal working day,
making it both economical and practical for clinical
laboratories. Further, the high sensitivity of the assay
allows it to be applied to in vitro cell-culture studies
where apolipoprotein B concentrations are extremely
low.
by western-blotting of both plasma and media samples. The
antibody was determined to be reactive with both apolipopro-
tein B-100 and apolipoprotein B-48. No cross-reactivity was
observed between the antibody and other apolipoproteins based
on immunoblotting of whole plasma'and HepG2 culture media
(data not shown).
Apolipoprotein B antibody-biotin conjugate
The biotinylation of the apolipoprotein B antibody was con-
ducted using a modification of a procedure by Bayer & Wilchek
(18). A solution of 0.5 mg apolipoprotein B antibody and 500
μΐ sodium borate buffer (0.1 mol/l pH 8.8) was prepared. The
solution was diaiyzed for 16 h at 4 °C against the borate buffer
to remove sodium azide. A solution of 1 mg N-hydroxysucci-
nimide biotin (Sigma Chemical Co., St. Louis MO) in 100 μΐ
dimethyl sulphoxide was prepared. A total of 250 μ§ of the
biotin ester was added with continuous mixing to the antibody
solution. Such a ratio of ester to antibody resulted in a high
probability that all the antibodies were biotinylated. The so-
lution was incubated for 2 h in the dark at room temperature.
The antibody-biotin conjugate was then treated with 50 μΐ of
1 mol/l NH4C1 for 10 min at room temperature. The prepara-
tion was then diaiyzed against phosphate buffered saline for
36 h to remove unbound biotin. Following dialysis, the anti-
body-biotin conjugate was stored at 4 °C and was stable for 3
months. The biotinylation procedure resulted in a molar ratio
of ester to antibody of more than 10:1. The antibody-biotin
conjugate working solution was prepared by dilution in 10
mmol/1 Tris pH 7.8 containing 3 g/1 bovine serum albumin and
0.4 mol/l KC1.
Materials and Methods
Blood and media samples
Blood was drawn at either Windsor Western Hospital or The
Windsor Red Cross from healthy donors by venipuncture into
EDTA-vacutainer tubes. The plasma was separated and stored
at — 20 °C. Media samples containing secreted proteins were
collected from cultures of human hepatoma cells (HepG2),
centrifuged to remove any cellular debris and then stored at
— 20 °C. A cocktail of protease inhibitors (1 mmol/1 benzami-
dine, 5 mmol/1 EDTA, 0.86 mmol/1 phenyl methyl sulphonyl
fluoride, 100 · 103 KIU/1 of aprotinin, 10 mmol/1 Hepes, 50
mg/1 leupeptin, 50 mg/1 pepstatin A) was added to all samples
immediately following their collection in order to prevent apo-
lipoprotein B degradation.
Apolipoprotein B standards and control
The apolipoprotein B standards and control (Atlantic Antibod-
ies, Scarborough, Maine) were diluted in phosphate buffered
saline containing 5 g/1 bovine serum albumin and 0.5 ml per
litre Tween-20. The concentrations of the standards and control
(Atlantic Antibodies) used in both the immunoturbidometric
and ELISA methods were based on a CDC reference material
(IUIS-WHO Apo-AI and B serum reference material) from the
CDC, Atlanta GA. Both the ELISA and the immunoturbido-
metric assays were calibrated with the same standards, which
were in turn standardized based on the CDC reference material.
The accuracy of the two methods was further examined by
running a commercial control material, the value of which was
also assigned based on the CDC reference material.
Apolipoprotein B ant ibody
The apolipoprotein B antibody used in this assay was an affin-
ity-purified IgG fraction obtained from Medix Biotech Inc,
Foster City CA. This preparation was thoroughly characterized
Enzyme conjugate solution
Either ExtrAvidin-alkaline phosphatase2) (Sigma) or streptavi-
din-alkaline phosphatase (Zymed Laboratories, San Francisco
CA) were diluted in Tris 0.1 mol/l pH 8 containing 0.5 mmol/1
MgCk
Substrate solution
Nitrophenyl-phosphate (BDH, Toronto), at a concentration of
4 g/1, was dissolved in 1 mol/l diethaiiolaniine pH 9.8 containing
0.5 mmol/1 MgCl2.
Coating procedure
Microtitre 8 well strips (Costar, Cambridge MA) were coated
with affinity-purified apolipoprotein B antibody that was di-
luted in 50 mmol/1 carbonate buffer, pH 9.6. A volume of 100
μΐ of the carbonate buffer containing 2 mg/1 of the antibody
was added into each well. The strips were covered and incubated
overnight at 4 °C. After the incubation period, the antibody
solution was aspirated and washed 3 times consecutively with
phosphate buffered saline containing 0.5 ml per litre Tween-20
using an ELISA plate washer (a Corning 8 channel washer was
used in this work). A solution containing 10 g/1 bovine serum
albumin in 250 μΐ aiiquots was dispensed into each well for l h
at room temperature to block any unbound sites. Following
this period, washing was performed 3 times.
Assay procedure
Hundred μΐ of either standard, control or serum that had been
diluted 1500-fold were added to the wells. Media samples were
added to the wells without diluting: After incubating for 2 h at
2) Enzyme: Alkaline phosphatase, Phosphoric monoester phos-
phohydrolase [alkaline optimum]: EC 3.1.3.1.
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room temperature the solutions was removed and washed with
phosphate buffered saline-Tween, as above. The antibody-bio-
tin solution was dispensed in volumes of 100 μΐ per well for l h
at room temperature. Washing was performed to remove any
unbound antibody-biotin conjugate. A 100 μΐ solution of the
enzyme-conjugate containing either ExtrAvidin-alkaline phos4·
phatase or streptavidin-alkaline phosphatase was added to each
well for l h at room temperature. After washing, 100 μΐ of the
substrate solution was added to each well. The reaction was
stopped by the addition of 100 μΐ of 0.3 mol/1 NaOH and the
absorbances read at 405 nm using a microplate reader (in this
study a Hyperion Micro Reader III, Hyperion Inc. Miami FL,
was used).
Results
Optimized assay conditions
We optimized the concentration of the apolipoprotein
Β antibody-biotin conjugate for use with two different
commercial preparations of the enzyme conjugate.
The biotinylated antibody was diluted in the range
25-fold to 390 625-fold when using ExtrAvidin-alka-
line phosphatase or 50-fold to 78125-fold when using
streptavidin-alkaline phosphatase conjugate (fig. 1).
The concentration of apolipoprotein B was kept con-
stant (1.34 g/1) and the assay carried out as described
above. The optimal dilution for the biotinylated an-
tibody was found to be 80-fold when used with
ExtrAvidin-alkaline phosphatase and 200-fold when
used with streptavidin alkaline phosphatase.
The dilution of the enzyme conjugate was also opti-
mized for both ExtrAvidin alkaline phosphatase and
streptavidin alkaline phosphatase (fig. 2). The optimal
dilution determined for both enzyme conjugates was
1000-fold.
The final optimization involved determining the op-
timal substrate incubation time (that which resulted
in a standard curve with the highest degree of linear-
ity) for the assay. The assay was performed under
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Fig. 1. Optimization of biotinylated apolipoprotein Β antibody. Apolipoprotein B ELISA was performed with various dilutions
of the biotinylated antibody using two preparations of enzyme conjugates, ExtrAvidin alkaline phosphatase (Sigma) (a)
and streptavidin alkaline phosphatase (Zymed) (b).
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Fig. 2. Optimization of enzyme-avidin conjugates. Apolipoprotein Β ELISA was performed with various dilutions of ExtrAvidin
alkaline phosphatase (a) and streptavidin alkaline phosphatase (b).
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Fig. 3. Optimization of the substrate incubation time. Apoli-
poprotein B ELISA was performed with different sub-
strate incubation times using either ExtrAvidin alkaline
phosphatase (a) or streptavidin alkaline phosphatase
(b). 5 min (o), 7 min (Δ), 10 min (^), 15 min (o).
conditions in which both the antibody-biotin conju-
gate and the enzyme-conjugates had been optimized.
The incubation time of the substrate was varied
(5-15 min) using either ExtrAvidin alkaline phos-
phatase (fig. 3A) or streptavidin alkaline phosphatase
(fig. 3B). The optimal incubation time was determined
to be 5 min using ExtrAvidin alkaline phosphatase
and 7 min using streptavidin alkaline phosphatase.
Figure 4 depicts the typical standard curves achieved
using the optimized conditions (Dilutions: standards
1500-fold, biotinylated antibody 80 or 200-fold, en-
zyme conjugate 1000-fold, substrate time 5 or 7 min).
An r value of 0.99 was consistently observed for the
standard curves. Comparisons of 3 typical standard
curves indicated a variation of 4-8% between cor-
responding data points.
Sensitivity and precision of the assay
Fig. 4. Representative standard curves obtained following op-
timization of the assay components:
assay conducted with ExtrAvidin alkaline phosphatase
as the enzyme^conjugate (o);
assay conducted with streptavidin alkaline phosphatase
as the enzyme conjugate (V).
within-run precision (CV), estimated by replicate
analysis (n = 10) of an apolipoprotein B control (1.39
g/1) was 3%. The between-run precision of the assay
was estimated by measuring the apolipoprotein B
control (n = 6) in 9 assays run over a 5-day period.
The between-run precision was determined to be 8%
at a concentration of 1.39 g/1. The assay was routinely
used to measure apolipoprotein B concentrations in
HepG2 media under control and hormonal conditions
such as insulin and triiodothyronine (19). Culture
media concentrations of 0.16 to 1.80 mg/l were meas-
ured directly without having to concentrate the sam-
ple. Media samples often required a 2-4-fold dilu-
tion. Using media samples, the within-run precision
was 5%, based on replicate analysis (n = 5) of two
media samples at concentrations of 1.88 and 1.10
mg/l.
Accuracy
A dilution experiment was conducted in order to
estimate the recovery of apolipoprotein B from a
dilution series. Such a procedure has been utilized to
estimate indirectly the accuray of immunoassays (20).
A plasma-based apolipoprotein B was diluted 1.5 to
12-fold, and apolipoprotein B ELISA was performed
on the diluted samples. The mean recovery of apoli^
poprotein B from the dilution series was 110%
(tab. 1).
Comparison with an immunoturbidometric
methodThe sensitivity, based on 2.5 times the standard de-
viation of the zero standard (n = 5) was determined Results of the assay were compared with those of an
to be 3 ng, with a working range of 18 -180 ng. The established immunoturbidometric method on COBAS
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 7
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Tab. 1. Recovery of apolipoprotein B from a sample of apoli-
poprotein B diluted in sample buffer
Dilution Apolipoprotein B Recovery
expected(g/D measured(g/D
one
1.5
2
3
4
8
12
0.971
0.728
0.485
0.364
0.182
0.121
1.457
0.875
0.715
0.515
0.442
0.217
0.165
Mean
90
98
106
120
119
136
110
0.0
0.2 0.4 0.6 0.8 1.0
Apolipoprotein B (ELISA) [g/Q
1.2
Fig. 5. Correlation between the biotin-avidin amplified ELISA
and an immunoturbidimetric method on COBAS-
FARA for the quantitation of apolipoprotein B.
FARA. Comparison resulted in a correlation of 0.92
with a slope of 1.48 and a y-intercept of —0.04 using
sera samples (n = 19) that had been diluted 1500-
fold (fig. 5).
Discussion
The use of a non-competitive ELISA for the assay of
apolipoprotein B offers several advantages over a
number of other assays used to quantitate apolipo-
protein B. It does not require that the particle size of
the antigen in the standards and samples be compa-
rable as is the case with several immunoprecipitin
assays. In addition, our assay is suitable both for
media and all types of sera (e. g. dyslipoproteinaetnic
sera), since it is not interfered with by turbidity. The
assay can also be easily adapted to an automation
procedure, unlike radial immunodiffusion and elec-
troimmunoassay techniques. Finally, it avoids the use
of radioisotopes, which in a clinical environment
poses a number of problems including special training
for staff in the handling and disposal of radioactive
material.
The precision and sensitivity of the present assay are
comparable to the radioimmunoassays used to meas-
ure apolipoprotein B (10). In addition, when com-
pared to other ELISAs the current method has a
sensitivity and precision comparable to or greater
than those assays reported to date (10, 13, 15, 21). A
non-competitive ELISA developed by James et al.
(1985) to quantitate apolipoprotein B reported a sen-
sitivity of 2.5 ng per assay with a working range of
10—100 ng. We report a sensitivity of 3 ng per assay
with a working range of 18 —180 ng. In addition, the
5 h required to perform this assay is an improvement
over several other ELISAs that cannot be easily per-
formed in a normal working day (8, 13, 15).
The current method compared well with an immu-
noturbidimetric method on an automated analyzer,
but a significant bias was observed between the two
methods. This discrepancy in the amount of antigen
detected may result from the ELISA procedure; de-
tecting a higher number of antigen molecules present
in the sample than that detected by the immunotur-
bidometric method. Since the sample is diluted con-
siderably in the ELISA method, more antigens may
become available for antibody recognition.
The high degree of sensitivity afforded by the use of
the biotin-avidin amplification system allows media
samples to be assayed directly, without the need for
concentrating the samples. The ELISA described here
has a sensitivity comparable to that of radioimmu-
noassay methods commonly used to measure media
apolipoprotein B concentrations. In addition, the use
of biotinylated antibody avoids the need for conju-
gating apolipoprotein B antibody to an enzyme. Di-
rect conjugation of antibody to enzymes has a number
of drawbacks which are avoided in our assay. The
high sensitivity of this assay requires that the stan-
dards and sera samples must be diluted considerably
in order to be measured. Such high dilution factors
have the potential for introducing considerable errors.
This does not appear to be a significant problem with
our assay as the within-run precision of the assay
performed manually was less than 5%. Automating*
the dilution of standards and samples should reduce
this acceptable imprecision even further.
The assay performed well using either of the two
commercial preparations of enzyme-avidin conju-
gates. However, it was possible to use the streptavidin
alkaline phosphatase conjugate with a higher dilution
of the biotinylated antibody, resulting in the use of
less reagent per assay. The use of streptavidin alkaline
phosphatase appeared also to result in standard
curves with lower intercepts, suggesting decreased
non-specific binding with this reagent. We are cur-
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rently adapting this non-competitive assay to quan-
titate other apolipoproteins such as apolipoprotein
A-I and E.
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